Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL28786919 | 0.89 | ENPP2 (0.42) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL1521671 | 0.89 | PRKCA (0.42) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL20111594 | 0.85 | FABP3 (0.43) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL26236288 | 0.85 | SELP (0.49) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL51010 | 0.85 | FABP3 (0.43) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL23761110 | 0.85 | FABP3 (0.43) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL29451071 | 0.85 | FABP3 (0.43) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| SCHEMBL234632 | 0.84 | P2RY10 (0.44) | — | |
| SCHEMBL23015250 | 0.84 | P2RY10 (0.44) | — | |
| SCHEMBL26236290 | 0.84 | LPAR3 (0.39) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120092088-A | Artificial nucleic acid molecules | 斯微(上海)生物科技股份有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120076798-A | Lipid composition | 斯微(上海)生物科技股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119654136-A | Lipid composition | 斯微(上海)生物科技股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119630426-A | Lipid composition | 斯微(上海)生物科技股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-118240844-B | Herpes zoster mRNA vaccine and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118480560-B | Respiratory syncytial virus mRNA vaccine and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118871586-A | Gene editing for improving joint function | 奥泽生物疗法公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118184538-B | Lung high-expression cationic lipid compound, composition containing same and application | 北京悦康科创医药科技股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118510788-A | Liposoamines | 摩登纳特斯有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118240844-A | Herpes zoster mRNA vaccine and preparation method and application thereof | 北京悦康科创医药科技股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-116375592-A | Novel long-acting low-toxicity cationic lipid compounds and compositions thereof | 北京悦康科创医药科技股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-116178193-A | High-efficiency low-toxicity and stable-expression cationic lipid compound and composition thereof | 北京悦康科创医药科技股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-114957027-B | Cationic lipid compound, composition containing cationic lipid compound and application of cationic lipid compound | 北京悦康科创医药科技股份有限公司 | 2023-05-19 | — | — | CN | claimed |
| CN-116082275-A | Spleen high-expression cationic lipid compound, composition containing same and application | 北京悦康科创医药科技股份有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-115784921-B | Extrahepatic targeting high-efficiency low-toxicity cationic lipid compound and composition thereof | 北京悦康科创医药科技股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115745820-B | Novel long-acting low-toxicity cationic lipid compounds and compositions thereof | 北京悦康科创医药科技股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| WO-2022214026-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2022-10-13 | — | — | WO | claimed |
| WO-2022214025-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED THEREBY, PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME, PREPARATION THEREOF, AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2022-10-13 | — | — | WO | claimed |
| EP-3778623-A1 | PHARMACEUTICAL COMPOSITIONS | Rhythm Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20160022764-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022764-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | ENPP2 315/4885LPAR3 104/4885LPAR1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.